Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response

American Journal of Clinical Nutrition

Volumn 96, Issue 5, 2012, Pages 1025-1031

  Weintraub, Steven J ^a,b   Fleckenstein, Jacquelyn F ^c   Marion, Tony N ^c   Madey, Margaret A ^c,e   Mahmoudi, Tahar M ^a   Schechtman, Kenneth B ^b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CROSS-SECTIONAL STUDY; EUROPEAN AMERICAN; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; RACE DIFFERENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ADULT; AFRICAN AMERICANS; AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VITAMIN D; YOUNG ADULT;

EID: 84867806781     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.039974     Document Type: Article

References (40)

1. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7. (Pubitemid 44142464)
2. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004;39:1702-8. (Pubitemid 38702672)
3. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non- Hispanic whites. N Engl J Med 2004;350:2265-71. (Pubitemid 38669209)
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
5. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
7. Thompson AJ. Genetic factors and hepatitis C virus infection. Gastroenterology 2012;142:1335-9.
8. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to in-terferon- based therapy in genotype 1 chronic hepatitis C. Hepatology 2010;51:1158-67.
9. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, Pasino M, Ieluzzi D, Cussigh A, Cmet S, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011;53:1118-26.
10. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, Bignulin S, Cmet S, Fontanini E, Falleti E, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011;24:43-50.
11. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005;15(4 suppl 5):S5-97-101.
12. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, Ceriani E, Fornasiere E, Pasino M, Ieluzzi D, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology (Epub ahead of print 18 May 2012).
13. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem S, Sarrazin C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferonalfa based therapy. J Hepatol 2011;54:887-93.
14. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients.World J Gastroenterol 2011;17: 5184-90.
15. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.e18.
16. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.
17. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.
18. Aloia JF. African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. Am J Clin Nutr 2008;88:545S-50S.
19. Aloia JF, Chen DG, Chen H. The 25(OH)D/PTH threshold in black women. J Clin Endocrinol Metab 2010;95:5069-73.
20. Barbour KE, Zmuda JM, Horwitz MJ, Strotmeyer ES, Boudreau R, Evans RW, Ensrud KE, Gordon CL, Petit MA, Patrick AL, et al. The association of serum 25-hydroxyvitamin D with indicators of bone quality in men of Caucasian and African ancestry. Osteoporos Int 2011; 22:2475-85.
21. Braun M, Palacios C, Wigertz K, Jackman LA, Bryant RJ, McCabe LD, Martin BR, McCabe GP, Peacock M, Weaver CM. Racial differences in skeletal calcium retention in adolescent girls with varied controlled calcium intakes. Am J Clin Nutr 2007;85:1657-63. (Pubitemid 46890437)
22. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997;12:958-66. (Pubitemid 27225007)
23. Cosman F, Nieves J, Dempster D, Lindsay R. Vitamin D economy in blacks. J Bone Miner Res 2007;22(suppl 2):V34-8. (Pubitemid 351304646)
24. Cosman F, Shen V, Morgan D, Gordon S, Parisien M, Nieves J, Lindsay R. Biochemical responses of bone metabolism to 1,25-dihydroxyvitamin D administration in black and white women. Osteoporos Int 2000;11:271-7. (Pubitemid 30216181)
25. Gutiérrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 2011;22:1745-53.
26. Leder BZ, Araujo AB, Travison TG, McKinlay JB. Racial and ethnic differences in bone turnover markers in men. J Clin Endocrinol Metab 2007;92:3453-7. (Pubitemid 47435319)
27. Meier DE, Luckey MM, Wallenstein S, Clemens TL, Orwoll ES, Waslien CI. Calcium, vitamin D, and parathyroid hormone status in young white and black women: association with racial differences in bone mass. J Clin Endocrinol Metab 1991;72:703-10. (Pubitemid 21921752)
28. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere MC, Malluche HH. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003;64:737-42. (Pubitemid 36871949)
29. Weaver CM, McCabe LD, McCabe GP, Braun M, Martin BR, Dimeglio LA, Peacock M. Vitamin D status and calcium metabolism in adolescent black and white girls on a range of controlled calcium intakes. J Clin Endocrinol Metab 2008;93:3907-14.
30. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-8. (Pubitemid 39565042)
31. Michos ED, Reis JP, Post WS, Lutsey PL, Gottesman RF, Mosley TH, Sharrett AR, Melamed ML. 25-Hydroxyvitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files. Nutrition 2012;28:367-71.
32. Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, Modlin RL, Martineau AR, Wilkinson RJ, Adams J, Hewison M. Vitamin Dbinding protein directs monocyte responses to 25-hydroxy- and 1,25- dihydroxyvitamin D. J Clin Endocrinol Metab 2010;95:3368-76.
33. Westwood SA, Seaman PJ, O'Brien C, Thorogood LJ. The phenotypic frequencies of group specific component and alpha-2-HS-glycoprotein in three ethnic groups. The use of these proteins as racial markers in forensic biology. Forensic Sci Int 1987;35:197-207. (Pubitemid 18002717)
34. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab 1998;83: 169-73. (Pubitemid 28498330)
35. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH,Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7. (Pubitemid 46144367)
36. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
37. Crawford BA, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006;3:689-99. (Pubitemid 44824697)
38. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010;55:2624-8.
39. Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Tov AB, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thio-acetamide- induced liver fibrosis in rats. Gut 2011;60:1728-37.
40. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-35. (Pubitemid 46489557)